Get started
Opus Genetics, Inc.Opus Genetics, Inc.Opus Genetics, Inc.

Opus Genetics, Inc.

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsETFs

Fundamentals and stats

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
R3X1 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company